Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry.
- Author:
Hyeon Gyu YI
1
;
Jin Seok KIM
;
Cheolwon SUH
;
Won Seog KIM
;
Jae Yong KWAK
;
Jong Seok LEE
;
Yang Soo KIM
;
Young Don JOO
;
Yoo Hong MIN
;
Hong Ghi LEE
;
Sung Soo YOON
;
Jong Ho WON
;
Seonyang PARK
;
Hugh Chul KIM
;
Chul Soo KIM
Author Information
- Publication Type:Original Article
- Keywords: Diffuse large B-cell lymphoma; Epidemiology; Survival; Rituximab; CHOP regimen
- MeSH: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Female; Hospitals, University; Humans; Korea; Lost to Follow-Up; Lymphoma; Lymphoma, B-Cell; Male; Prednisolone; Prevalence; Vincristine; Rituximab
- From:Blood Research 2013;48(2):115-120
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. METHODS: In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990. RESULTS: Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration. CONCLUSION: The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.
